English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Core competence
Technology
Bispecific
Proprietary ADC Platform
Mix-mAb
Publications
Pipeline
Overview
Envafolimab(KN035)
KN046
KN026
JSKN003
KN026+KN046
KN019
KN052
Investors
Information Disclosure
Corporate Governance
Stock Information
IR Contacts
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Core competence
Technology
Bispecific
Proprietary ADC Platform
Mix-mAb
Publications
Pipeline
Overview
Envafolimab(KN035)
KN046
KN026
JSKN003
KN026+KN046
KN019
KN052
Investors
Information Disclosure
Corporate Governance
Stock Information
IR Contacts
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
NEWS
Press Release
Media Report
Year:
Select
2020
2019
2018
2017
Media Report
14
June 2020
ENDPOINTS NEWS
Sanofi sharpens focus on bispecifics, and China, with Alphamab deal
14
June 2020
ENDPOINTS NEWS
Two years in, Hong Kong's biotech experiment has been validated
14
May 2020
PharmaBoardroom
Alphamab Oncology is Committed to Developing Portfolio and Generating Value for Stakeholders
13
December 2019
BIOWORLD
Bispecific antibody specialist Alphamab raises $234M on HKEX
13
December 2019
ENDPOINTS NEWS
Alphamab Oncology rounds out HKEX's second biotech IPO year with $230M raise and high local interest
12
December 2019
BIOCENTURY
Local demand high for Alphamab Oncology’s Hong Kong IPO
04
December 2019
BIOCENTURY
Alphamab Oncology sets sights on $220M IPO as HKSE continues to gain momentum
27
December 2019
BIOWORLD
Alphamab hauls in $60M series B, eyes HKEX listing to advance bispecific platform
30
May 2019
ENDPOINTS NEWS
Ready to harvest its PD-L1, Alphamab reloads with $60M to nurture the bispecific patch
19
November 2018
ENDPOINTS NEWS
Seeking an edge in the global I/O race, Alphamab Oncology loads up $100M-plus from marquee backers
1
2
PREV
1/2
NEXT
